Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma is a research paper published in Cancers (2020). On theSindex it has a DataRank of 0. It has been cited 22 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: U54HD16014
National Institutes of Health
Grant: P30CA082709
Jeff Gordon Research Foundation
Grant: NA
National Institutes of Health
Grant: 3P30CA082709-16S3
Indiana University Melvin and Bren Simon Cancer Center Support Grant
FWCI
0.90
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 2 of 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis
Additional file 2 of 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis
Additional file 1 of 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis
Additional file 1 of 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis